title: Psychosocial issues and outcomes in maternal PKU.
abstract: Elevated phenylalanine (Phe) levels in pregnant women with PKU are teratogenic. Fetal damage due to elevated maternal Phe levels during pregnancy is known as maternal phenylketonuria (MPKU). The risk of birth defects in MPKU, including global developmental delays, microcephaly, congenital heart disease, and low birth weight, can be dramatically reduced by controlling Phe levels during pregnancy (metabolic control). Phe levels should be maintained in the range of 120-360 micromol/L, ideally starting before pregnancy begins (i.e., when planning a pregnancy). If control is not achieved before pregnancy (e.g., if the pregnancy was unplanned), good outcomes are still possible if metabolic control is established by 8 weeks of pregnancy. Unfortunately, metabolic control before and during pregnancy can be poor. As well, many mothers stop treatment after pregnancy, which can decrease the mother's ability to focus on her child and increase her risk of behavioral and psychological problems. This can have a negative effect on the home environment. Many factors affect adherence to the strict diet used to control Phe levels, including poor access to medical care, lack of reimbursement for medical foods (in some regions, such as parts of the United States), practical difficulties with implementing the diet, financial constraints, demographics, and psychosocial issues. A comprehensive treatment approach that begins prior to pregnancy and continues after the infant is born may help to improve the management of MPKU. This approach should include education of girls about MPKU at an early age, interventions to prevent unplanned pregnancies, psychosocial support, improved treatment access and reimbursement for medical foods, and treatment guidelines. Treatments such as sapropterin may also have a role in improving metabolic control during pregnancy.
authors.affiliation: University of Southern California/Keck School of Medicine, Department of Pediatrics, Genetics Division, 2125 Ames St., Los Angeles, CA 90027, USA. drpku@sbcglobal.net
authors.forename: Richard
authors.initials: R
authors.lastname: Koch
authors.forename: Friedrich
authors.initials: F
authors.lastname: Trefz
authors.forename: Susan
authors.initials: S
authors.lastname: Waisbren
mesh_terms: D005260:Female; D006801:Humans; D010661:Phenylketonurias / Q000378:metabolism / Q000503:physiopathology* / Q000523:psychology*; D011247:Pregnancy; D011248:Pregnancy Complications / Q000378:metabolism / Q000503:physiopathology* / Q000523:psychology*; D011261:Pregnancy Trimester, First; D014443:Tyrosine / Q000008:administration & dosage
chemical_list: D014443:Tyrosine